3B Blackbio DX Ltd Q1 FY27 Earnings Analysis

- The company targets a revenue growth of 15% to 20% for FY27 and onward. - Coris is expected to contribute around INR50 crores in topline, growing slightly with EBITDA turning slightly positive in FY27, targeting 5%-10% EBITDA margin by FY28. - The overall consolidated topline for FY27 is expected to be INR175-180 crores. - The Indian domestic market is expected to grow around 15%, with international operations growing 20%-25%, leading to consolidated growth of 15%-20%. - Competition from China affects a small product segment but is not expected to impact the core high-margin AMR panel business. - Market growth is anticipated at 8%-10% over the next 2-3 years, with the company maintaining approximately 15% market share. - Growth is supported by new product launches such as sample-to-answer systems expected around Q3-Q4, and ongoing US FDA approvals enhancing global presence.

- 3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28. - EBITDA margins are projected to maintain or slightly improve, with consolidated EBITDA margins expected around 40%-45% excluding other income. - Coris segment is anticipated to become slightly EBITDA positive in FY27, aiming for 5% to 10% EBITDA margin by FY28. - Overall EBITDA growth is expected to mirror revenue growth (15%-20%), with Coris EBITDA flat or marginally positive in the near term. - Depreciation for FY27 is estimated around INR 4.5 to 5 crores annually. - The company plans strong margin profiles supported by high-margin segments like AMR; competitive pressure from China is limited to a small product segment. - EPS growth is implied aligned with revenue and EBITDA growth targets, though specific EPS figures were not disclosed.

- The company is well-positioned for expansion, currently utilizing around 50% of its capacity. - Expected capex for capacity expansion is relatively low, approximately INR 4-5 crores. - Free cash flow generation is strong, about INR 40 crores plus annually, leading to a significant cash balance available for investments. - There is a clear focus on inorganic growth through M&A, with multiple consultants appointed in France, UK, and US to scout opportunities. - M&A targets typically have a minimum topline of EUR 2 million, preferably EBITDA positive or turnaround candidates. - The company aims to keep a cash reserve of INR 50 crores specifically for M&A deals. - Slight uncertainties exist on timing; M&A closures are expected during the year but exact Q1/Q2 timing is not guaranteed. - Treasury investments are diversified into equity mutual funds (5-7%), fixed deposits (30-35%), treasury bonds (30-35%), and AAA-rated corporate bonds, maintaining liquidity for acquisitions.

- There is no explicit mention of any current or planned fundraising through debt or equity. - The company is holding significant cash and investments (~INR230 crores) and plans to use this for M&A opportunities. - Management mentions a preference to keep reserves (~INR50 crores) to be ready for acquisitions rather than raising fresh capital. - Expansion needs minimal capital (INR4-5 crores), supported by strong free cash flow (~INR40 crores annually). - No concrete timeline for raising funds; focus is on utilizing existing treasury assets and internal accruals. - M&A discussions are ongoing with hopes to close deals within the year but depend on valuation and due diligence, not fundraising. - Overall, emphasis is on organic growth and acquisitions funded by internal cash rather than fresh equity or debt.

- Coris contract initially was Euro 6 million for four years starting 2024. - Out of Euro 6 million, approximately Euro 3.45 million has been executed (2.1 million + 1.35 million). - Around Euro 2.4 million remains to be executed through FY28. - The Coris HAT order is expected to remain broadly similar in the current year. - Exact timing of order execution can be affected by external factors like Ebola outbreak in Congo, causing possible delays. - For FY27, Coris is expected to be around INR 50 crores in revenue with EBITDA roughly flat or slightly positive. - Market demand projected to grow at 8% to 10%, with 3B BlackBio maintaining around 15% market share. - No major market glut expected from China or competitors in India or export markets due to regulatory barriers.